<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084591</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000365462</org_study_id>
    <secondary_id>P30CA006927</secondary_id>
    <secondary_id>FCCC-03606</secondary_id>
    <nct_id>NCT00084591</nct_id>
  </id_info>
  <brief_title>Intensity-Modulated Radiation Therapy With Incorporated Boost and Capecitabine Before Surgery in Treating Patients With Locally Advanced Rectal Cancer</brief_title>
  <official_title>Phase I Study of Preoperative Intensity Modulated Radiation Therapy (IMRT) With Incorporated Boost and Oral Capecitabine in Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells.&#xD;
      Intensity-modulated radiation therapy (radiation directed at the tumor more precisely than in&#xD;
      standard radiation therapy) with incorporated boost (an increase in the amount of radiation&#xD;
      given during treatment) may cause less damage to normal tissue. Drugs used in chemotherapy,&#xD;
      such as capecitabine, work in different ways to stop tumor cells from dividing so they stop&#xD;
      growing or die. Giving radiation therapy together with chemotherapy before surgery may shrink&#xD;
      the tumor so it can be removed.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of neoadjuvant&#xD;
      intensity-modulated radiation therapy with incorporated boost when given together with&#xD;
      capecitabine in treating patients with locally advanced rectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of neoadjuvant boost intensity-modulated&#xD;
           radiotherapy when combined with capecitabine before surgery in patients with locally&#xD;
           advanced rectal cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the pathologic tumor response in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the quality of life of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of boost intensity-modulated radiotherapy (IMRT).&#xD;
&#xD;
      Patients undergo neoadjuvant IMRT with incorporated boost once daily 5 days a week for 5&#xD;
      weeks. Beginning on the first day of radiotherapy, patients receive oral capecitabine twice&#xD;
      daily 7 days a week for 5 weeks. Patients undergo surgical resection 4-8 weeks after&#xD;
      completion of chemoradiotherapy.&#xD;
&#xD;
      Cohorts of 3-6 patients undergo escalating doses of boost IMRT until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 3&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline, at week 5 of chemoradiotherapy, before surgery, and&#xD;
      then at 1, 3, and 12 months after surgery.&#xD;
&#xD;
      Patients are followed at 1, 3, and 12 months after surgery.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 3-15 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Acute toxicity by CTCAE at 6 weeks following study completion</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed by Quality of Life Questionnaire Core 30 Items (QLQ-C30) before and after radiotherapy and then every 6 months after surgery</measure>
  </secondary_outcome>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed primary adenocarcinoma of the rectum&#xD;
&#xD;
               -  Distal border of the tumor within 12 cm of the anal verge by proctoscopic exam&#xD;
&#xD;
               -  Clinical stage T3-4, N1-2 (stage II or III) disease by 2 of the following tests:&#xD;
&#xD;
                    -  Physical exam&#xD;
&#xD;
                    -  Transrectal ultrasound&#xD;
&#xD;
                    -  Pelvic CT scan&#xD;
&#xD;
                    -  Pelvic MRI&#xD;
&#xD;
          -  No clinical evidence of metastatic disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  No known, uncontrolled coagulopathy&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT and SGPT ≤ 1.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times normal&#xD;
&#xD;
          -  Creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No clinically significant cardiac disease&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No symptomatic coronary artery disease&#xD;
&#xD;
          -  No poorly controlled cardiac arrhythmias&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No active inflammatory bowel disease&#xD;
&#xD;
          -  No lack of physical integrity of the upper gastrointestinal tract&#xD;
&#xD;
          -  No malabsorption syndrome&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other prior or concurrent malignancy except inactive, non-invasive carcinoma of the&#xD;
             cervix or non-melanoma skin cancer&#xD;
&#xD;
          -  No concurrent serious, uncontrolled infection(s)&#xD;
&#xD;
          -  No prior unanticipated severe reaction to fluoropyrimidine therapy&#xD;
&#xD;
          -  No known sensitivity to fluorouracil&#xD;
&#xD;
          -  No prior uncontrolled seizures&#xD;
&#xD;
          -  No CNS disorders that would preclude study participation&#xD;
&#xD;
          -  No other medical or psychiatric condition that would preclude study participation&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior immunotherapy for rectal cancer&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for rectal cancer&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy for rectal cancer&#xD;
&#xD;
          -  No prior pelvic radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery and recovered&#xD;
&#xD;
          -  No prior surgery for rectal cancer&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since prior participation in another investigational drug study&#xD;
&#xD;
          -  No concurrent celecoxib&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Freedman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>February 11, 2010</last_update_submitted>
  <last_update_submitted_qc>February 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2010</last_update_posted>
  <keyword>stage II rectal cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

